Here are five observations:
1. The FDA approved Viberzi at 75 mg and 100 mg for a 12-week treatment.
2. Patients suffering from IBS-D can take the pill twice a day.
3. Allergen’s stock rose 0.49 percent during the last trading session, reaching $293.22.
4. The company outperformed the S&P 500 by 9.6 percent.
5. Allergen develops medical aesthetics, generic, branded generic, biosimilar and over-the-counter pharmaceutical products.
More articles on gastroenterology:
GI physician leader to know: Dr. David Greenwald of Mount Sinai Hospital
Olympus’ modified duodenoscope receives FDA approval, EndoChoice stock lowered to “sell” & more — 4 GI/endoscopy company key notes
Are gastroenterologist’s patient biases & political leanings related? 4 statistics
